Clinical trials in New Haven, CT

215 recruiting studies have a site in or near New Haven, CT, Connecticut.

Top conditions here

All conditions

Showing 40 of 215 studies

RecruitingPhase 3NCT06136650

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Sponsor: Merck Sharp & Dohme LLC

New Haven, CT · +62 more sites

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Hartford, CT · New Haven, CT · +452 more sites

RecruitingPhase 3NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Sponsor: Pierre Fabre Medicament

New Haven, CT · +39 more sites

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Derby, CT · Fairfield, CT · Greenwich, CT · +1147 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Hartford, CT · New Haven, CT · +113 more sites

RecruitingPhase 3NCT07513376

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Sponsor: Merck Sharp & Dohme LLC

New Haven, CT · +23 more sites

RecruitingPhase 3NCT07525206

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Sponsor: AbbVie

New Haven, CT · +17 more sites

RecruitingPhase 3NCT04965675

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Sponsor: H. Lundbeck A/S

New Haven, CT · Stamford, CT · +20 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

New Haven, CT · +174 more sites

RecruitingPhase 1NCT06179069

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Sponsor: Zai Lab (Shanghai) Co., Ltd.

New Haven, CT · +10 more sites

RecruitingPhase 1NCT06565195

A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

Sponsor: Prevail Therapeutics

New Haven, CT · +6 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

New Haven, CT · Norwich, CT · +52 more sites

RecruitingPhase 1 / Phase 2NCT07038343

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Sponsor: Avenzo Therapeutics, Inc.

New Haven, CT · +18 more sites

RecruitingPhase 1 / Phase 2NCT07061574

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Sponsor: City of Hope Medical Center

New Haven, CT · +10 more sites

RecruitingPhase 2NCT05798923

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Sponsor: IRulya Therapeutics Inc.

New Haven, CT · +3 more sites

RecruitingPhase 3NCT07177352

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Sponsor: Hoffmann-La Roche

New Haven, CT · +67 more sites

RecruitingPhase 3NCT07424404

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company

New Haven, CT · +55 more sites

RecruitingPhase 3NCT05164172

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Sponsor: H. Lundbeck A/S

New Haven, CT · Stamford, CT · +18 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

New Haven, CT · West Haven, CT · +223 more sites

RecruitingPhase 1 / Phase 2NCT05786924

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Sponsor: Institut de Recherches Internationales Servier

New Haven, CT · +20 more sites

RecruitingPhase 3NCT06312176

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Sponsor: Merck Sharp & Dohme LLC

New Haven, CT · Stamford, CT · +44 more sites

RecruitingPhase 3NCT06430801

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Sponsor: Merck Sharp & Dohme LLC

Hamden, CT · New Haven, CT · +85 more sites

RecruitingPhase 3NCT06736574

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Sponsor: Cytokinetics

Bridgeport, CT · Hartford, CT · New Haven, CT · +85 more sites

RecruitingPhase 3NCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Sponsor: Merck Sharp & Dohme LLC

New Haven, CT · +38 more sites

RecruitingPhase 3NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Sponsor: Merck Sharp & Dohme LLC

New Haven, CT · +52 more sites

RecruitingPhase 3NCT07007312

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Sponsor: Kura Oncology, Inc.

Hartford, CT · New Haven, CT · +42 more sites

RecruitingPhase 3NCT07088068

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Sponsor: Sanofi

New Haven, CT · +33 more sites

RecruitingPhase 3NCT07351045

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Sponsor: Hoffmann-La Roche

New Haven, CT · +43 more sites

RecruitingPhase 1NCT07519655

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

Sponsor: Pfizer

New Haven, CT · +8 more sites

RecruitingPhase 1NCT07660731

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

Sponsor: Pfizer

New Haven, CT

RecruitingPhase 3NCT07667803

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Sponsor: AstraZeneca

New Haven, CT · +55 more sites

RecruitingNot applicableNCT05776563

Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)

Sponsor: Yale University

New Haven, CT

RecruitingPhase 2NCT06031688

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Derby, CT · Fairfield, CT · Glastonbury, CT · +275 more sites

RecruitingPhase 2NCT06749210

DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY

Sponsor: Ohio State University Comprehensive Cancer Center

New Haven, CT · +1 more sites

RecruitingPhase 1 / Phase 2NCT07070232

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Sponsor: BioNTech SE

Hartford, CT · New Haven, CT · +17 more sites

RecruitingPhase 3NCT03678025

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Sponsor: SWOG Cancer Research Network

Guilford, CT · New Haven, CT · Stamford, CT · +331 more sites

RecruitingPhase 2NCT07033494

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Sponsor: Merck Sharp & Dohme LLC

New Haven, CT · +35 more sites

RecruitingPhase 1NCT07751991

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

Sponsor: Charm Therapeutics

New Haven, CT · +2 more sites

RecruitingPhase 3NCT07794579

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Sponsor: Eli Lilly and Company

New Haven, CT · Waterbury, CT · +78 more sites

RecruitingPhase 1 / Phase 2NCT05919264

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Sponsor: Parabilis Medicines, Inc.

New Haven, CT · +30 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.